Status:

COMPLETED

Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

High Risk for Breast Cancer

Risk Reduction Behavior

Eligibility:

FEMALE

35-100 years

Phase:

NA

Brief Summary

Background: * Chemoprevention is the use of preventive medications to reduce the risk of breast cancer for women who are at a high risk of developing the disease. Although the treatment has shown eff...

Detailed Description

BACKGROUND: * Breast cancer chemoprevention has been notably underutilized. * Barriers to integrating breast cancer risk reducing measures include: lack of time, low priority of risk reduction in com...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Women with no history of cancer other than cervical carcinoma in situ or non-melanoma skin cancer
  • High risk for breast cancer based on at least one of the following:
  • Gail score \> 1.67
  • History of atypical hyperplasia (either ductal or lobular)
  • History of lobular carcinoma in situ
  • Documentation of a deleterious BRCA1 or BRCA2 mutation
  • Considering a decision about chemoprevention with tamoxifen or raloxifene
  • Access to an IBM-compatible or MacIntosh personal computer with broadband Internet access
  • Access to an email account
  • Access to a telephone
  • Aged 35 or older
  • Able to communicate in English verbally and in writing
  • Women of all races and ethnic groups are eligible for this study.
  • EXCLUSION CRITERIA:
  • Concurrent participation in another cancer chemoprevention study
  • Prior history of cancer, other than cervical carcinoma in situ or non-melanoma skin cancer
  • Ever taken tamoxifen or raloxifene
  • Age less than 35
  • Unable to communicate in English verbally and in writing
  • No computer with internet access
  • No email account
  • No telephone

Exclusion

    Key Trial Info

    Start Date :

    May 18 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    May 26 2010

    Estimated Enrollment :

    64 Patients enrolled

    Trial Details

    Trial ID

    NCT00906321

    Start Date

    May 18 2009

    End Date

    May 26 2010

    Last Update

    July 2 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Cancer Institute (NCI), 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892